2016
Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study
PAŘENICA, Jiří; Petr KALA; Monika PÁVKOVÁ GOLDBERGOVÁ; Josef TOMANDL; Jindřich ŠPINAR et al.Základní údaje
Originální název
Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study
Autoři
PAŘENICA, Jiří; Petr KALA; Monika PÁVKOVÁ GOLDBERGOVÁ; Josef TOMANDL ORCID; Jindřich ŠPINAR; Simona LITTNEROVÁ; Jiří JARKOVSKÝ ORCID; A. MEBAZAA; Marie TOMANDLOVÁ; Milan DASTYCH; Jana GOTTWALDOVÁ a E. GAYAT
Vydání
International Journal of Cardiology, Clare (Ireland), Elsevier Ireland Ltd. 2016, 0167-5273
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 6.189
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/16:00092115
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Biomarker; Natriuretic peptide; ST-segment elevation myocardial infarction; Prognosis
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 12. 2016 10:33, Soňa Böhmová
Anotace
V originále
Background: Blood-based biomarkers have a prognostic value in patients with myocardial infarction. The aim of our prospective observational cohort study was to evaluate the prognostic value of biomarkers of different pathophysiological pathways for the occurrence of 1-year all-cause mortality and hospitalisation due to acute heart failure. Methods and results: In 593 patients with ST-segment elevation MI (STEMI) treated by primary PCI, biomarkers were evaluated at 24 h after MI onset. A minimum of three-year follow-up was achieved in all patients. The combination of 1-year all-cause mortality and hospitalisation due to heart failure was the primary endpoint. A cohort for validation of our combined GRACE-natriuretic peptide (NP) score included 667 STEMI patients. The primary endpoint was reached in 9.3% of patients. Among 21 biomarkers, only B-type natriuretic peptide (BNP), NT-proBNP, superoxide dismutase and nitrite/nitrate, added to clinical GRACE score led to a significant increase in the area under the curve of C statistics, in comparison to GRACE alone (tested by Delong's test). Continuous net reclassification improvement and integrated discrimination index demonstrated an improved reclassification and discrimination of the GRACE model for SOD, BNP and NT-proBNP, and improved reclassification for nitrite/nitrate. Consistent results for this new combined prognostic model GRACE-NP were found also for a validation cohort. Conclusions: The levels of NP have an additional value to the prognostic properties of the GRACE score for the prediction of the combined endpoint of one-year mortality or hospitalisation for AHF. Nitrite/nitrate and SOD are strong prognostic factors, even on top of the GRACE score.
Návaznosti
| MUNI/A/1362/2015, interní kód MU |
|